Status and phase
Conditions
Treatments
About
This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD) effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in Japanese subjects with non-valvular atrial fibrillation (originally described in Japanese).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Japanese subjects with non-valvular AF who met all of the following criteria:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
102 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal